Cellulitis
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
He wāhi noa te waewae mō Cellulitis.
Take angamaheni.
Wāhanga whakaora.
relevance score : -100.0%
ReferencesKo te cellulitis he mate kiri huakita noa. Neke atu i te 14 miriona ngā tāngata e pā ana ia tau i te United States. Ka tata ki te $3.7 piriona te utu mō te tiaki i ngā tūraroranga me te 650,000 ngā whare hōhipera ia tau. Ko te tikanga, ka puta te cellulitis hei wāhi mahana, whero i runga i te kiri, te pupuhi, me te ngawari. Nā te mate huakita ohorere, ka puta te mumura ki ngā papa kiri hohonu me ngā kiko tata. Kāore he puku, he nana rānei kei tēnei mate. Ko te streptococci beta-hemolytic, inā koa ko te rōpū A streptococcus (Streptococcus pyogenes), ko ngā kaipahua o mua, ka whai ko methicillin-sensitive Staphylococcus aureus.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
Cellulitis is a common bacterial skin infection, with over 14 million cases occurring in the United States annually. It accounts for approximately 3.7 billion dollars in ambulatory care costs and 650000 hospitalizations annually. Cellulitis typically presents as a poorly demarcated, warm, erythematous area with associated edema and tenderness to palpation. It is an acute bacterial infection causing inflammation of the deep dermis and surrounding subcutaneous tissue. The infection is without an abscess or purulent discharge. Beta-hemolytic streptococci typically cause cellulitis, generally group A streptococcus (i.e., Streptococcus pyogenes), followed by methicillin-sensitive Staphylococcus aureus. Patients who are immunocompromised, colonized with methicillin-resistant Staphylococcus aureus, bitten by animals, or have comorbidities such as diabetes mellitus may become infected with other bacteria.
Ko te cellulitis he mate huakita o te kiri me ngā kopa ngohe. Ka puta ina he take ki te arai whakamarumaru o te kiri, te pūnaha aukati, te tōhanga toto rānei. Ko te mate huka, te nui, me te koroheketanga ka piki ake te tūpono o te cellulitis mā te pā ki ēnei wāhi. Ka titiro anō mātou ki ngā kitenga tata nei mō te whakamārama i te cellulitis, e whakaatu ana i te hiranga o te tātaritanga tika, nā te mea ko ngā āhuatanga pērā i te ngoikoretanga o te uaua, te eczema, te thrombosis uaua hohonu, me te kauti, he maha tonu te pohehe ki te cellulitis. Ko ngā patu‑paturopi e whakamahia ana ki te rongoā i te cellulitis ka āta whiriwhiria kia aro ki ngā huakita noa, ā, kaua e akiaki i te aukati paturopi. Ka kōrero anō mātou mō ngā patu‑paturopi hou kua whakaaetia mō te cellulitis. Ka hoki mai anō te cellulitis nā te mea kei te haere tonu ngā āhuatanga morearea me te kino o te pūnaha lymphatic.
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
Cellulitis is a bacterial infection of the skin and soft tissues. It happens when there are issues with the skin's protective barrier, the immune system, or blood circulation. Diabetes, obesity, and old age increase the chances of cellulitis by affecting these areas. We also look at recent findings on diagnosing cellulitis, highlighting the importance of accurate diagnosis since conditions like venous insufficiency, eczema, deep vein thrombosis, and gout are often confused with cellulitis. Antibiotics used to treat cellulitis are chosen carefully to target common bacteria without encouraging antibiotic resistance. We also talk about new antibiotics approved for cellulitis. Cellulitis often comes back because of ongoing risk factors and damage to the lymphatic system..
He maha ngā tangata e haere ana ki ngā hōhipera, ki ngā rūma ohorere rānei mō ngā māte kiri huakita ohorere. Ko Staphylococcus aureus te iroriki matua e puta ai ēnei māte, ā, ka uaua te rongoā nā te mea he atete ētahi riaka ki ngā paturopi noa.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
Acute bacterial skin and skin-structure infections are a common reason for seeking care at acute healthcare facilities, including emergency departments. Staphylococcus aureus is the most common organism associated with these infections, and the emergence of community-associated methicillin-resistant Staphylococcus aureus (MRSA) has represented a considerable challenge in their treatment.
Ka taea te wehe i te Staphylococcus aureus ki ngā momo e rua i runga i ō rātou whakautu ki ngā paturoopu: methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA). I roto i ngā tekau tau kua pahure ake nei, nā te whanaketanga huakita me te nui o te whakamahinga o ngā paturoopu, kua piki ake te aukati o te S. aureus ki ngā rāua tērā, ā, kua piki ake te reiti o te mate MRSA i te ao.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
According to the sensitivity to antibiotic drugs, S. aureus can be divided into methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA). In recent decades, due to the evolution of bacteria and the abuse of antibiotics, the drug resistance of S. aureus has gradually increased, the infection rate of MRSA has increased worldwide.
To review the salient features of the management of severe skin and soft tissue infections (SSTIs), including toxic shock syndrome, myonecrosis/gas gangrene, and necrotizing fasciitis.
Ko ngā waewae me te kanohi ngā wāhi e tino kitea ana. Ko ngā mea mōrearea ko te momona, te pupuhi o ngā waewae, me te koroheketanga. Ko ngā huakita e pā nui ana ko te streptococci me te Staphylococcus aureus.
Ko te tikanga, ko te maimoatanga me ngā paturopi ka tangohia e te mākau, pērā i te cephalexin, amoxicillin, cloxacillin rānei. Tata ki te 95 % o ngā tāngata ka pai ake i muri i te 7 ki te 10 rā o te maimoatanga. Ki te hunga e mate huka ana, he kino ake ngā hua.
Ko te cellulitis he māuiui noa, ā, i te United Kingdom, ko te cellulitis te take mō te 1.6 % o ngā whakaurunga ki te hōhipera. I te tau 2015, i mate tata ki te 16,900 ngā hunga puta noa i te ao.
○ Maimoatanga - Rongoā OTC
Ko te cellulitis matatau me maimoatanga me ngā patu paturopi kua tohua e te tākuta anake. Mēnā ka tere haere te māuiui, ka piri ki te kirikiri me te makariri, me kite wawe e te tākuta. Ko te tono hinu paturopi i runga i te hoko‑kore ki ngā patunga mō te ārai ka awhina pea. Mēnā he angiangi rawa te tono o te hinu, kāore pea e whai hua.
#Polysporin
#Bacitracin
#Betadine
Whakamahia ngā rongoā māuiui OTC pērā i te acetaminophen hei whakamāmā i te mamae.
#Ibuprofen
#Naproxen
#Acetaminophen
Kia mā te waewae me te rongoā i te waewae o te kaipara, nā te mea ka nui ake te pānga o te cellulitis ki te waewae o te kaipara.
○ Maimoatanga
#First-generation cephalosporins (e.g. Cefradine)
#Bacterial culture
#Third-generation cephalosporins (e.g. Cefditoren Pivoxil)